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Summary The number of patients suffering from tuberculosis (TB) globally is increasing. Due to
the HIVepidemic, most patients suffering from TB reside in sub-Saharan Africa. In order to improve
TB diagnostics, new tests — interferon-gamma release assays (IGRAs) — have been developed over
the last decade. In this paper we evaluate the possible use of these tests in diagnosing or excluding
active TB in high HIV-burden, resource-limited settings. The inability to differentiate between
active and latent TB, limited data on IGRA performance in HIV-infected patients, observed false-
negative results, high costs, and logistic problems limit the potential benefit of IGRAs. We also
present two theoretical study designs in order to further assess IGRAs. Setting up a study on this
subject is complicated by the frequent unavailability of mycobacterial cultures, the difficulty in
acquiring prospective data, and the impossibility of denying treatment to a patient suspected of
having active TB. We feel that current evidence does not support the implementing of IGRAs in
clinical practice in settingswith high endemic latent TB infection (LTBI) and high HIV prevalence. As
these settings are the ones that suffer the most from the TB epidemic, we believe that the role of
IGRAs in global TB control is questionable.
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Fuelled by the HIV epidemic, the number of tuberculosis (TB)
patients in sub-Saharan Africa is increasing to almost
unprecedented levels.1,2 The majority of the HIV/TB co-
infected patients reside in sub-Saharan Africa, resulting inPublished by Elsevier Ltd. All rights reserved.
e2 R.E. Barth et al.high morbidity and mortality levels in that area.3 The World
Health Organization has called for ‘‘urgent and extraordinary
actions’’ to control tuberculosis in Africa and launched the
‘Global plan to stop tuberculosis’, highlighting the need for
accurate, simple, and low-cost diagnostic tests for the detec-
tion of TB infection.4,5 In order to control the TB epidemic,
the ability to make an adequate TB diagnosis in resource-
limited settings is essential. However, diagnosing TB is chal-
lenging, especially in immunocompromised patients.
The gold standard test for the diagnosis of active TB is
culture ofMycobacterium tuberculosis (MTB) in patients with
signs and symptoms of active TB. In some patients it is not
possible to isolate MTB from clinical specimens, or obtain
clinical specimens. In HIV-positive patients with TB, an
increased proportion of smear-negative and extrapulmonary
disease is found.6 Logistic reasons, such as time needed to
culture MTB and costs, are additional reasons why culture is
often omitted. Lacking a definite mycobacterial culture in
patients suspected of having active TB, the decision to treat
is often based on clinical signs and symptoms or typical
findings on chest X-ray, whether or not combined with
acid-fast bacilli (AFB) in sputum smear.
In 2006 the antenatal HIV seroprevalence in South Africa
was 29% and the annual TB notification rate exceeded 700/
100 000.7 Because it is nearly impossible to convincingly
exclude TB in primary care clinics in such a high-endemic
TB country, and for fear of missing patients who are suffering
from TB, the threshold to start anti-tuberculosis treatment is
low. This might result in a considerable number of patients
who are unnecessarily being exposed to a six-month course of
tuberculostatics with the associated risks, side effects, and
costs. On the other hand, a TB diagnosis may be missed in
patients who are suffering from active TB, but who do not
have clear symptoms (such as prolonged cough, fever, weight
loss, night sweats, or lymphadenopathy) and have a normal
chest X-ray and negative AFB on smears, thus running the risk
of unnecessary morbidity andmortality and possibly infecting
others.
The century-old tuberculin skin test (TST) has low speci-
ficity due to false-positive results in populations vaccinated
with bacille Calmette—Gue´rin (BCG) and in patients infected
with most non-tuberculous mycobacteria.8 TST also has low
sensitivity in immunocompromised patients and is therefore
not recommended for this group by some of the current
guidelines.9
In order to improve TB diagnostics and care worldwide,
simple and reliable tests are needed to reduce false-positive
and false-negative results (inherent in TST), equipping clin-
icians with more accurate tools for TB diagnosis, control, and
elimination. However, the frequent inability to definitely
confirm the presence of active TB by culture, hampers
assessment of the accuracy of new TB tests.
Interferon-gamma release assays (IGRAs) for TB have been
developed over the last decade.10 Two IGRAs are currently
commercially available, the QuantiFERON-TB Gold test (Cel-
lestis, Carnegie, Australia) and the T-SPOT.TB assay (Oxford
Immunotec, Oxford, UK). Both tests measure the interferon-
gamma release by sensitized lymphocytes in response to
specific MTB antigens, using methods such as ELISA (Quanti-
FERON) and enzyme-linked immunospot assay (T-SPOT.TB).
IGRAs are considered positive when the amount of produced
interferon is over a certain threshold. For reliable results,normal lymphocyte function is crucial. An indeterminate test
result is usually due to reduced interferon-gamma production
after stimulation with a non-specific antigen (phytohemag-
glutinin), resulting in a failed positive control. This often
reflects underlying immunosuppression.10
As IGRAs are based on the cellular immune response, they
are incapable of distinguishing between a latent and an
active TB infection.
In our view, IGRAs are of little value in diagnosing or
excluding active TB in high HIV-burden, resource-limited set-
tings — areas where the TB epidemic rages most fiercely. We
describe below the reasons why we believe this is the case,
briefly summarize current evidence, and discuss theoretical
study designs in order to further assess IGRAs in such settings.
Sensitivity and specificity of IGRAs
A number of papers on IGRA performance have been pub-
lished. Sensitivity has been estimated by testing people with
a confirmed pulmonary TB and specificity has been calculated
in low-endemic countries with a high BCG vaccination rate.
For immunocompetent patients, sensitivity is estimated to
be between 83% and 97% for the T-SPOT.TB test and between
70% and 89% for the QuantiFERON-TB Gold test.11—16 Speci-
ficity would be 96—98% for the QuantiFERON-TB Gold test and
might be even higher for the T-SPOT.TB test.11,12,17,18 Lacking
a gold standard for the diagnosis of a latent TB infection
(LTBI), most studies have compared IGRA results to the
results of TSTs.11—14,16,17 They have shown higher specificity
(especially in BCG-vaccinated populations) and sensitivity
rates for the IGRAs as compared to the TST. This is an
important advantage of IGRAs over the TST, as BCG vaccine
coverage is high in many sub-Saharan African countries. In
South Africa, for example, coverage is over 95%.19
Diagnostic research on IGRAs
These studies, however, could all be seen as ‘test research’ as
opposed to ‘diagnostic research’. In test research, studies
merely focus on the ‘characteristics’ of a test, such as
sensitivity and specificity, instead of on the test’s perfor-
mance to confirm or exclude a diagnosis. Diagnostic research,
on the other hand, refers to studies that aim to quantify a
test’s added contribution beyond test results readily avail-
able to the physician in determining the presence or absence
of a particular disease, in this case TB.20 A single test’s
sensitivity and specificity are of limited value in practice
as they reflect the probability that a particular test result is
positive or negative given the presence (sensitivity) or
absence (specificity) of a disease. In practice, however,
one is interested in the probability of having a particular
disease given the test result. In order to determine whether
or not a person is suffering from TB, a test has to truly
increase, or decrease, the probability of disease presence
as estimated from the previous data, such as clinical signs and
symptoms, X-rays, and sputum tests. The ‘post-test prob-
ability’ should be greater or smaller than the ‘pre-test
probability’.21 If such a test were available and affordable
for TB, it would be of great value in high-endemic countries.
When setting up diagnostic research in order to calculate
what added value implementing IGRAs in a sub-Saharan
IGRAs in high-endemic settings e3African setting could have for the diagnosis of active TB,
several issues have to be addressed. As already mentioned,
IGRAs cannot differentiate between latent and active TB. In
people infected with HIV, treating LTBI with isoniazid reduces
the risk of developing active TB, but there is no evidence that
such preventive therapy reduces all-cause mortality.22
Although some do consider the use of mass isoniazid pre-
ventive therapy for HIV-infected individuals,23 the imple-
mentation of LTBI treatment in resource-limited settings is
limited due to difficulty in the identification of those at risk
for developing active TB, uncertainty about effectiveness of
preventive treatment in high-endemic areas, costs, and fear
of enhancing the spread of resistant TB.24—26 If diagnosing
LTBI does not have therapeutic consequences, testing for it
does not seem beneficial. Active TB on the other hand will be
treated. So a benefit of implementing IGRAs in settings where
there is a high LTBI prevalence, but where treating LTBI is not
common practice, could only be expected if it were possible
to reliably confirm or exclude active TB on the basis of IGRA
results.
Prevalence of latent TB
Before being able to estimate the potential use of IGRAs in
predicting active TB, the prevalence of latent TB should be
determined. Lacking a gold standard test for LTBI, the exact
prevalence cannot be calculated. Estimations have been
made, however, using TSTs as well as IGRAs. In a recent
case—control study in Cape Town, South Africa, TSTs and
both IGRAs were each positive in over 70% of HIV-negative
controls, indicating a very high community exposure to M.
tuberculosis.27 In another report from Khayelitsha, South
Africa, an LTBI prevalence of 80% was estimated.23 A person
who does not show signs or symptoms indicating an active TB
infection and who has a positive IGRA in such a setting would
be considered to have latent and not active TB.
Predictive values of IGRAs
Could IGRAs then play a role in reducing the number of
patients who are needlessly being exposed to tuberculo-
statics? If so, this would decrease morbidity and costs for
both patients and healthcare facilities and would therefore
be valuable. Before receiving tuberculostatics, patients have
to present with signs or symptoms indicating TB. Within this
group of patients that are eligible for TB treatment, three
groups of patients can be distinguished. The first and prob-
ably largest group consists of patients who have been diag-
nosed with TB correctly. The second group of patients
consists of those who have an LTBI, but whose actual signs
and symptoms are caused by a different ailment, and the last
group of patients will have neither active, nor latent TB.
Ideally it should be possible to determine which patients are
in the second and third groups and withhold TB treatment
from them. A positive IGRA cannot differentiate between the
first two groups, but is it correct to assign a patient to the
third group if the IGRA result is negative? Or, in other words,
what is the negative predictive value of IGRAs?
As prospective data on IGRAs are limited, predictive
values of these tests are not known. An ideal study design
to determine the predictive values would be a prospectivecohort study where patients, clinically suspected of having
active TB, but with negative IGRA and sputum-test results,
would be denied TB treatment and would be followed up to
see if those who tested IGRA-positive actually develop active
TB and those who tested negative stay well. Such a study is
not feasible, however, for obvious ethical reasons.
A prospective study that followed up persons who had
tested IGRA-negative in an LTBI screening program showed
that no patient with a negative test result subsequently
developed active TB.28 This study was set in an area where
TB prevalence is low, and none of the studied persons had
signs or symptoms indicative of TB. The pretest probability of
developing a new TB infection in such a setting is much lower,
and therefore one could state that the generalizability of
these results is limited. Another prospective study concluded
that negative QuantiFERON test results should not be used to
exclude the diagnosis of TB in persons with suggestive signs or
symptoms, as 14 out of 69 patients with culture-confirmed TB
had a negative QuantiFERON test result.29 The US Centers for
Disease Control and Prevention came to the same conclusion
and state in their guidelines that a negative QuantiFERON
test cannot be used alone to exclude the diagnosis of active
tuberculosis.30
Test validity in immunocompromised
patients
Another issue when determining whether or not it is justifi-
able to withhold TB treatment from people who test IGRA-
negative, is the test’s validity in immunocompromised
patients. Impaired immune functionality can possibly reduce
interferon-gamma responses, and in the severely immuno-
compromised the test may be impaired by T-cell anergy.31
Data on the performance of these tests in HIV-positive
patients, especially in patients with low CD4 T-cell counts,
are still limited though. Most studies are case—control stu-
dies on diagnosing LTBI,31,32 often comparing IGRA results to
TSToutcomes.27,33,34 Studies on the performance of IGRAs in
HIV-infected patients suspected of having active TB are even
scarcer, and in most only a subgroup of patients is HIV-
positive.13,23,29,35,36 Moreover, a high frequency of indeter-
minate IGRA results in immunocompromised patients has
consistently been shown, especially where the QuantiFERON
test is used.13,29,36,37 The number of indeterminate results
seems to be somewhat lower with the T-SPOT.TB assay.32,34,38
Two theoretical study designs
In 2006, a group of experts gave directions for future research
on IGRAs.39 Test performance in high-risk populations, such as
those with HIV infection, was considered an important
research question. In order to study if IGRAs would be useful
in diagnosing active TB in HIV-positive patients, we consid-
ered two study designs. One possible design would be to
include all patients eligible for tuberculostatics, i.e., those
suspected of having active TB. By splitting the group accord-
ing to HIV status and after performing an IGRA for each
patient, the 2  2 table shown in Table 1 can be constructed.
Even though the negative predictive value of the IGRAs is
unknown, some will regard a negative IGRA result in an
immunocompetent patient sufficient to withhold TB
Table 1 2  2 Contingency table IGRA results depending on
HIV status
All patients suspected
of active TB
IGRA result (QuantiFERON-
TB/T-SPOT.TB)
HIV status Positive Negative
Negative A B
Positive C D
IGRA, interferon-gamma release assay; TB, tuberculosis.
e4 R.E. Barth et al.treatment and actively search for an alternative diagno-
sis.40—42 Assuming that the proportion of patients who actu-
ally have a TB infection (latent or active) and those who have
not is the same for HIV-positive and HIV-negative patients,
one could decide to withhold TB treatment from all patients
with a negative IGRA result if the proportion of IGRA-negative
patients in HIV-positive patients (D/C) does not differ too
much from that in HIV-negative patients (B/A). If the pre-
valence of LTBI is high, for example 70%, the number of
patients with suspected TB and a negative IGRA result would
be low.
Let us say that at least 80% of HIV-negative patients
suspected of having active TB will test IGRA-positive. If a
10% difference in test results between HIV-positive and HIV-
negative patients is still considered acceptable, and one
wants to test the null-hypothesis that this is the case, a
study population of 6609 patients is needed. A more realisticTable 2 Power calculations for a theoretical study design on the u
assumptions on the proportion of HIV-negative patients testing IGR
positive and HIV-negative patients are used to calculate the numb
Assumed percentage of HIV-neg patients
with a positive IGRA test result
(‘A’ in Table 1)
Difference in IGR
HIV-pos and HIV-
acceptable (‘D/C
60% 25%
20%
15%
10%
5%
70% 25%
20%
15%
10%
5%
80% 25%
20%
15%
10%
5%
90% 25%
20%
15%
10%
5%
IGRA, interferon-gamma release assay; TB, tuberculosis.
a N Group: number of patients needed per group.
b N Total: total number of patients needed for the study.scenario, for example with the assumption of only 10% of HIV-
negative patients having a negative IGRA result, will already
call for a study population of 14 950 patients. Accepting a
difference in test results between HIV-positive and HIV-nega-
tive patients of only 5%, increases this number to 25 782.
Power calculations for various assumptions on the proportion
of HIV-negative patients testing IGRA-positive and for various
differences in test results between HIV-positive and HIV-
negative patients are shown in Table 2.
Even if it is possible to set up and finance a study with
enough participants in order to test such a hypothesis, we
still do not know the exact significance of a negative test
result. Prospective follow-up would be needed to show if
these patients indeed stay free of tuberculosis, and in many
resource-limited settings such follow-up is not feasible.
Another possible study design would be to include patients
eligible for tuberculostatic treatment, but split the group
according to the sputum smear results instead of their HIV
status. By doing this, the 2  2 table shown in Table 3 can be
constructed.
Although patients who are not suffering from TB, but who
have AFB in their sputum have been described previously,43
pulmonary disease due to environmental mycobacteria is
very rare.44 The positive sputum smear could thus serve as
an alternative ‘gold standard’ for the diagnosis of active TB,
and patients with a positive sputum test could be used as a
reference for the other groups.
If an immunocompetent patient is AFB- and IGRA-negative
(D), it might be justified to withhold TB treatment from himse of IGRAs to exclude active TB in HIV-positive patients. Various
A-positive and various differences in test results between HIV-
er of patients needed for a study
A test results between
neg patients deemed
’ versus ‘B/A’ in Table 1)
N Groupa N Total b
407 814
628 1256
1101 2202
2439 4878
9592 19 184
649 1298
996 1992
1737 3474
3829 7658
14 988 29 976
1133 2266
1732 3464
3009 6018
6609 13 218
25 782 51 564
2586 5172
3940 7880
6825 13 650
14 950 29 900
>25 000 >50 000
Table 3 2  2 Contingency table IGRA results depending on
sputum smear (AFB) results
All patients suspected
of active TB
IGRA result QuantiFERON-
TB/T-SPOT.TB
Sputum smear (AFB) Positive Negative
Positive A B
Negative C D
IGRA, interferon-gamma release assay; AFB, acid-fast bacilli; TB,
tuberculosis.
IGRAs in high-endemic settings e5or her. However, many patients are co-infected with HIV and
TB. As mentioned earlier, HIV co-infection increases the
probability of having a negative sputum test as well as testing
IGRA-negative. Being associated with both the exposure as
well as the outcome, HIV co-infection is an important con-
founder and will decrease the internal validity of the study. If
all HIV-positive patients are excluded in order to avoid this
problem, the internal validity will increase, but the external
validity and thus generalizability, of the study will decrease.
A possible solution to this problem would be to analyze data
from HIV-negative and HIV-positive patients separately,
enabling a comparison of the results later on.
Costs and logistics
Apart from methodological problems in setting up studies on
the use of IGRAs in diagnosing active TB and in interpreting
IGRA test results, there are other hurdles to be overcome
when implementing IGRAs in resource-limited settings. Using
IGRAs in clinical practice will result in a substantial financial
and logistic burden on healthcare institutions and labora-
tories. Therefore, future research on cost-effectiveness will
also be needed.
Conclusions
In summary, the inability to differentiate between active
and latent TB, the limited data on IGRA performance in HIV-
infected patients, the observed false-negative results, high
costs, and logistic problems limit the potential benefit of
IGRAs in the diagnosis of active TB. Setting up a study on
this subject is complicated further by the frequent unavail-
ability of mycobacterial cultures, difficulty in acquiring
prospective data, and the impossibility of denying treat-
ment to a patient suspected of having active TB. We there-
fore feel that current evidence does not support the
implementing of IGRAs in clinical practice in settings with
high-endemic LTBI and high HIV prevalence. As these set-
tings are the ones that suffer the most from the TB epi-
demic, we believe that the role of IGRAs in global TB control
is questionable. If the results of future research make it
possible to differentiate between latent and active TB
(possibly by defining separate interferon-gamma cut-off
values), or if more evidence is published on the perfor-
mance of IGRAs in HIV-infected patients, the area in which
IGRAs are useful might expand.
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